ANAPTYSBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 639.63K shares, a 2617.91% increase year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 563.32K shares, a 1196.86% increase year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 509.79K shares, a 4534.46% increase year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 68.80K shares, a 64.95% decline year-over-year.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 645.56K shares, a 128.75% increase from fiscal 2024.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 282.21K shares, a 210.52% increase from fiscal 2023.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 90.88K shares, a 89.12% decline from fiscal 2022.
- ANAPTYSBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 835.16K shares, a 206.52% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 639.63K shares derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | 1.78M shares derived: sum of 4 quarters · filed 2026-09-21 |
| 2026-03-31 | 563.32K shares 10-Q · filed 2026-05-12 | 1.17M shares derived: sum of 4 quarters · filed 2026-09-21 |
| 2025-12-31 | 509.79K shares derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | 645.56K shares 10-KT · filed 2026-09-21 |
| 2025-09-30 | 68.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 146.77K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 23.53K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 274.27K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 43.44K shares 10-Q · filed 2025-05-05 | 272.57K shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 11.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 282.21K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 196.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 271.21K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 21.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | 89.79K shares derived: sum of 4 quarters · filed 2024-08-05 |
| 2024-03-31 | 53.08K shares 10-Q · filed 2024-05-09 | 88.80K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 90.88K shares 10-K · filed 2024-03-11 |
| 2023-09-30 | 14.88K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 240.07K shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 20.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | 348.01K shares derived: sum of 4 quarters · filed 2023-08-07 |
| 2023-03-31 | 55.16K shares 10-Q · filed 2023-05-11 | 359.98K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 149.19K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | 835.16K shares 10-K · filed 2023-03-01 |
| 2022-09-30 | 122.82K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 860.22K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 32.81K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 758.58K shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 530.34K shares 10-Q · filed 2022-05-04 | 791.02K shares derived: sum of 4 quarters · filed 2022-05-04 |
| 2021-12-31 | 174.25K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07 | 272.46K shares 10-K · filed 2022-03-07 |
| 2021-09-30 | 21.17K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 107.56K shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 65.25K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | 145.27K shares derived: sum of 4 quarters · filed 2021-08-09 |
| 2021-03-31 | 11.78K shares 10-Q · filed 2021-05-04 | 90.24K shares derived: sum of 4 quarters · filed 2021-05-04 |
| 2020-12-31 | 9.35K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | 100.49K shares 10-K · filed 2021-02-25 |
| 2020-09-30 | 58.89K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | 248.19K shares derived: sum of 4 quarters · filed 2020-11-04 |
| 2020-06-30 | 10.22K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | 242.81K shares derived: sum of 4 quarters · filed 2020-08-10 |
| 2020-03-31 | 22.03K shares 10-Q · filed 2020-05-06 | 270.82K shares derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-12-31 | 157.04K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | 333.26K shares 10-K · filed 2020-03-02 |
| 2019-09-30 | 53.52K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | 349.33K shares derived: sum of 4 quarters · filed 2019-11-08 |
| 2019-06-30 | 38.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | 486.02K shares derived: sum of 4 quarters · filed 2019-08-08 |
| 2019-03-31 | 84.47K shares 10-Q · filed 2019-05-07 | 659.03K shares derived: sum of 4 quarters · filed 2019-05-07 |
| 2018-12-31 | 173.11K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | 583.66K shares 10-K · filed 2019-02-28 |
| 2018-09-30 | 190.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 432.88K shares derived: sum of 4 quarters · filed 2018-11-08 |
| 2018-06-30 | 211.24K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | 302.06K shares derived: sum of 4 quarters · filed 2018-08-07 |
| 2018-03-31 | 9.10K shares 10-Q · filed 2018-05-08 | 131.43K shares derived: sum of 4 quarters · filed 2018-05-08 |
| 2017-12-31 | 22.33K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | 199.19K shares 10-K · filed 2018-03-05 |
| 2017-09-30 | 59.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | |
| 2017-06-30 | 40.61K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | |
| 2017-03-31 | 76.86K shares 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |